Ohio State Navbar

Our Team

Arnab Chakravarti, MD


 

 

 

Chair and Professor, Department of Radiation Oncology
Max Morehouse Chair in Cancer Research
Director, Brain Tumor Program

 

 

 

 

 

 


Faculty, Hospital and Clinical Appointments

March 2009 – Present

Chair and Professor
Department of Radiation Oncology
Max Morehouse Chair of Cancer Research
Director, Brain Tumor Program
Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard L. Solove Research Institute
The Ohio State University College of Medicine Columbus, Ohio

2012 – Present

Board of Directors
Ohio State University Physicians
Faculty Group Practice

2009 – 2012

CEO
Ohio State University Physicians, Radiation Oncology, LLC

2005 – 2009

Associate Professor
Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts
 
Associate Radiation Oncologist
Massachusetts General Hospital, Boston, Massachusetts
 
2002 – 2005
Assistant Professor
Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts
 
2000 – 2002
Instructor 
Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts

Honors and Awards

  • 1988 – 1990: President of LINC, Duke University Volunteer Agency
  • 1986 – 1990: Golden Key National Honor Society
  • 1988: Duke University Scholarship Recipient, Study at Cambridge University, England
  • 1988 – 1990: Dean’s List with Distinction, Duke University
  • 1990: Graduation with Highest Distinction in Economics, Duke University
  • 1992: Research Internship Grant, University of Virginia
  • 1995: Southern Medical Association Annual Physician-In-Training Award
  • 1997: New England Cancer Society Annual Resident/Fellow Award
  • 1999: AACR Award to attend AACR Molecular Oncology Seminar, Aspen, Colorado
  • 1999: David Livingston Award, Massachusetts General Hospital
  • 1999: American Association for Cancer Research (AACR) / AFLAC Scholar Award
  • 1999: American Society for Therapeutic Radiology and Oncology Resident Basic Clinical Science Research Award
  • 2000: AACR–Glaxo-Wellcome Scholar Award
  • 2001: American Association for Cancer Research-Novartis Research Award
  • 2001: American Society for Therapeutic Radiology and Oncology (ASTRO) Young Investigator Basic Science Award
  • 2004: Radiation Therapy Oncology Group (RTOG) Simon Kramer Award
  • 2005 – 2008: Press Ganey Award for Superior Patient Care, Massachusetts General Hospital/Harvard Medical School
  • 2008: Lucien J. Rubinstein Memorial Award American Brain Tumor, Association (ABTA) – (Trainee: Anshu Shukla)
  • 2008: RTOG Next Generation Investigator Award
  • 2009: AACR Scholar Award (Trainee: Kamalakannan Palanichamy, PhD)
  • 2011 – Present: Castle-Connolly Top Doctors  
  • 2011 – Present: Castle-Connolly Top Doctors for Cancer
  • 2011 – Present: Columbus Magazine Top Doctors
  • 2012 – Present: Best Doctors, Inc. Award
  • 2013 – 2015: Press Ganey Award for Highest Patient Satisfaction in Radiation Oncology in USA (99th percentile nationally)
  • 2015: Worldwide Registry Award of Top Doctors
  • 2015: Newsweek Magazine America’s Top Cancer Doctors

Committee Memberships

Ohio State University

  • 2009 - Present: Dean’s Promotion and Tenure Committee
  • 2009 - 2012: CEO, Ohio State University Physicians Radiation Oncology, LLC
  • 2009 - 2011: Member, Dean's Roundtable
  • 2011 - 2013: Member, Pelotonia Grant Review Committee
  • 2012 - Present: Board of Directors, Ohio Neuro-Oncology Consortium (ONO-C)
  • 2013: Member, OSU Clinical Trials Office - Time to trials committee
Harvard Medical School
  • 2000 - 2009: Voting Member, Institutional Review Board (IRB), Partners/Dana Farber/Harvard Cancer Center
  • 2002 - 2009: Brain Tumor Protocol Review Committee, Massachusetts General Hospital/Harvard Medical School
  • 2003 - Present: Radiation Oncology Course Director, Massachusetts General Hospital/Harvard             Medical School. 
  • 2004 - 2009: Clerkship Director, Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School
  • 2005 - 2009: Executive Committee Member, Harvard Medical School Radiation Oncology Residency Program
International/National
  • 1999 - Present: Translational Research Steering Committee, Member/Principal Investigator, RadiationTherapy and Oncology Group (RTOG- an NCI-supported clinical trials group)
  • 1999 - Present: GU Translational Research Steering Committee, Member/Principal Investigator,           Radiation Therapy and Oncology Group (RTOG), (National Study Chair on Prostate DNA Microarray Protocol)
  • 2000 - Present: RTOG Brain Tumor Research/Steering Committee, Member
  • 2002 - 2009, 2012: Society for Neuro-Oncology (SNO), Scientific Program Committee
  • 2002 - 2012: American Society for Therapeutic Radiology and Oncology (ASTRO) Scientific Program Committee.
  • 2005 - Present: Chair, RTOG Brain Tumor Translational Research Committee
  • 2006 - Present: Co-Chair, RTOG Brain Tumor Clinical Committee
  • 2006 - Present: RTOG Publications Committee
  • 2006, 2012: Oxford University (Oxford, United Kingdom): External Advisory Board for Radiation Oncology Research Program
  • 2006: Chair, ASTRO Scientific Program Committee on CNS Malignancies
  • 2006 - 2009: Vice Chair, SNO Membership Committee
  • 2008 - Present: American Board of Radiology: Radiation Oncology Specialty Board Examiner (Written)
  • 2009: American Association for Cancer Research Scientific Program Committee
  • 2010 - Present: European Organisation for the Research and Treatment of Cancer (EORTC) Steering Committee – North American Delegate
  • 2010: Board of Directors, International Society for Radiation Neuro-Biology
  • 2010 - Present: National Institutes of Health, Standing Member, Cancer Biomarkers Study Section (CBSS)
  • 2011: Scientific Program Chair, BIT Life Sciences Meeting, Beijing, China
  • 2011: Scientific Program Chair, Pepcon Meeting, China
  • 2012: Scientific Program Committee, American College of Radiation Oncology
  • 2012 - Present: Examiner, American Board of Radiology: Radiation Oncology Oral Board 
  • 2012 - 2015: American Society for Clinical Oncology (ASCO) Conquer Cancer Foundation Grants Committee
  • 2012 - 2014: American Association for Cancer Research (AACR) Gertrude Elion Research Awards Committee
  • 2014 - Present: Chair, NRG Brain Tumor Translational Research Committee
  • 2014 - Present: Co-Chair NRG Brain Tumor Clinical Committee
  • 2014 - Present: RTOG Foundation Advisory Board
  • 2013 - 2015: Scientific Program Chair, American College of Radiation Oncology (ACRO)

Society Memberships

  • 1995 - Present: Massachusetts Medical Society, Member
  • 1996 - Present: American Society for Therapeutic Radiology and Oncology, Member
  • 1996 - Present: American College of Radiology, Member
  • 1998 - Present: American Association for Cancer Research, Member
  • 1999 - Present: American Association for the Advancement of Science, Member
  • 2000 - Present: American Medical Association, Member
  • 2001 - Present: American Society for Clinical Oncology, Member
  • 2002 - Present: Society for Neuro-Oncology
  • 2007 - Present: Radiation Research Society
  • 2009 - Present: Society for Chairs in Academic Radiation Oncology Programs

Specialty Boards

  • 2000 - Present: American Board of Radiology (in Radiation Oncology - recertified 2010)

Editorial Boards

  • 2006: Cancer Investigation
  • 2006 - Present: Neuro-Oncology
  • 2006 - Present: Journal of Neuro-Oncology
  • 2009 - Present: Radiation Oncology
  • 2009 - Present: Currents in Signal Transduction
  • 2011 - Present: World Journal of Neurology
  • 2011 - Present: Currents in Pharmaceutical Therapies
  • 2011 - Present: Frontiers in Radiation Oncology
  • 2011 - Present: Frontiers in Neuro-Oncology (Associate Editor)
  • 2011 - Present: Radiation Medicine Rounds Brain Cancer
  • 2011 - Present: Scientific World Journal

Journal Reviewer

  • 2004 - Present: Review Board, Journal of the National Cancer Institute
  • 2004 - Present: Review Board, Cancer Research
  • 2004 - Present: Review Board, Clinical Cancer Research
  • 2004 - Present: Review Board: Journal of Clinical Oncology
  • 2004 - Present: Review Board: International Journal of Radiation Oncology, Biology, and Physics
  • 2005 - Present: British Journal of Cancer
  • 2005 - Present: Cancer
  • 2005 - Present: New England Journal of Medicine
  • 2005 - Present: Journal of the American Medical Association
  • 2006 - Present: International Journal of Cancer

Funding 

  • NIH/NCI - K08CA82163
    P.I.: Arnab Chakravarti, M.D.
    Investigating the mechanism of pRB tumor suppression
    10/1/99 – 9/30/04
    Direct Costs=$125,000/year.
  • NIH/NCI (CTEP)-R03PAPP01 Radiation Therapy Oncology Group
    (Multi-institutional NCI-funded clinical trials group in oncology)

    National Study Chair: Arnab Chakravarti, M.D.
    Protocol 1007 - A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (Iressa) with Radiation Therapy in Patients with Glioblastoma Multiforme.
    Direct Costs = $100,000
  • Radiation Therapy Oncology Group
    (Multi-institutional NCI-funded clinical trials group in oncology)

    P.I. Arnab Chakravarti, M.D.
    Molecular markers in prostate cancer
    7/2000 – 7/2001
    Direct Costs = $50,000
  • Radiation Therapy Oncology Group
    P.I. Arnab Chakravarti, M.D.
    Investigating the role of EGFR in radiation resistance
    1/2001 - 1/2002
    Direct Costs = $25,000
  • Radiation Therapy Oncology Group
    P.I. Arnab Chakravarti, M.D.
    Investigating the role of surviving in mediating radiation resistance in prostate and bladder cancers
    2002
    Direct Costs = $50,000
  • Radiation Therapy Oncology Group
    P.I. Arnab Chakravarti, M.D.
    DNA Microarray Analysis of Prostate Cancer
    7/2003 – 7/2005
    Direct Costs = $50,000
  • Goldhirsh Brain Tumor Research Award
    P.I.: Arnab Chakravarti, M.D.:
    The Role of PI3K Signaling in Glioblastoma;
    7/2003 – 7/2006
    Direct Costs = $200,000/year
  • Claire and John Bertucci Award for Surviving Research in Prostate Cancer
    Co-PI’s: Arnab Chakravarti, M.D. and Anthony Zietman, M.D.
    7/2003 – 6/2005
    Direct Costs = $100,000
  • NIH/NCI-RO1CA108633
    PI: Arnab Chakravarti, M.D.
    Signal Transduction Pathways in Glioblastoma
    9/2009 – 3/2011
    Total Direct Costs = $381,333
  • Brain Tumor Funders Group Grant
    PI: Arnab Chakravarti, M.D. and Minesh Mehta
    Identifying and Overcoming Resistance Mechanisms in Glioblastomas
    04/2009 – 10/2011
    Total Direct Costs = $592,029
  • Goldhirsh Brain Tumor Research Award
    P.I.: Arnab Chakravarti, M.D.
    The Role of Survivin in Mediating Radiation Resistance in Glioblastoma;
    7/2006 – 6/2007
    Direct Costs =$100,000
  • NIH/NCI 1RC2CA148190
    PI: Arnab Chakravarti, M.D.
    Towards a Refined Molecular Recursive Partitioning Analysis Scheme for Glioblastomas
    09/2009 – 08/2012
    Total Direct Costs = $526,904
  • Radiation Therapy Oncology Group (RTOG)
    Institutional P.I. (Active- Chakravarti)
    Direct Costs = $150,000/year
  • TRP 91
    PI: Chakravarti
    Expression of VEGF and VEGF receptors, Flt-1 and Flk-1 in Bladder Cancers
    03/2011 – 8/2012
  • TRP 92/Study based on RTOG 9802
    PI: Chakravarti
    Prognostic and predictive markers in low-grade gliomas
    03/2011 – 12/2015
    Total Direct Costs: 11,222
  • Department of Health and Human Services Affordable Care Act Grant
    Administrative PI Schuller, Radiation Oncology PI: Arnab Chakravarti
    Personalized Care Delivery in Radiation Oncology
    Direct Costs = $100,000,000 (Active)
    (These funds have been used to expand the clinical and research infrastructure of OSU Radiation Oncology)
  • NIH/NCI 1U10CA180850-01
    Multiple PI Mechanism: Goldberg, Chakravarti, Cohn, Blum, Naughton
    OSU as a Network Lead Academic Participating Site for the NCI NCTN (Score = 14)
    5/2014 – 2/2019 (Active)
    Current Direct Costs: $898,089
  • NIH/NCI 2K12CA133250-06
    PI: Byrd, Co PI: Chakravarti
    OSU K12 Training Grant for Clinical Faculty Investigators (Score = 10).
    9/2008 – 5/2016 (Active)
    Current Direct Costs: $746,352
  • NIH/NCI/CTEP 1R01CA169368
    PI: Houghton; Co-PI: Chakravarti
    Therapeutic exploitation of BRAF for Astrocytoma
    7/2013 – 9/2014
    Total Direct Costs: $48,355
  • NIH/NCI 1R01CA11522358
    Multiple-PI R01: Chakravarti, Xia
    Novel functions of Pyruvate kinases M2 in DNA double-strand break repair (A0 Score = 12th percentile).
    9/2014 – 8/2019
    Total Direct Costs: $275,691
  • NIH/NCI 1R01CA1145128
    PI: Baroukhim, Co-PI: Chakravarti
    Genetic Evolution of Glioblastomas during Radiation and Temozolomide Therapy (Pending, Score = 8th percentile).
    4/2015 – 3/2020
    Current Direct Costs: $33,200

Peer-Reviewed Original Articles
(2009-Present)

  •  Zhang M, Ho A,Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, Pollack A, Chakravarti A.  Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1033-42.
  • Franks,D.; Mukherjee, N.; Black, P.; Loeffler,J.; Chakravarti, A. Stat-3 gene expression is associated with poor prognosis in GBM. Translational Oncogenomics (in press).
  • Sperduto, P.; Chakravarti, A.; Aldape, K.; Burger, P.; Papermaster, G.B.; Sperduto, P. Twenty-Year Survival in Glioblastoma: A Case Report and Molecular Profile. Int J. Radiat Oncol Biol Phys. Mar 25, 2009 (epub ahead of print).
  • Russo, A.L.; Kwon, H.C.; Burgan, W.E.; Carter, D.; Beam, K.; Weizheng, X.; Zhang, J.; Slusher, B.S.; Chakravarti, A.; Tofilon, P.J.; Camphausen, K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 15(2):607-612, 2009.
  •  Zhang, M.; Ho, A.; Hammond, E.H.; Suzuki, Y.; Bermudez, R.S.; Lee, R.J.; Pilepich, M.; Shipley, W.; Khor, L.Y.; Pollack, A.; Chakravarti, A. Prognostic value of survivin in locally advanced prostate cancer: a Study based on RTOG 8610. Int J. Radiat Oncol Biol Phys. 73(4):1033-1042, 2009.
  • Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, Chakravarti A. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1095-103.
  •  Lu, K.; Zhu, S.; Cvrljevic, A.; Huang, T.; Sarkaria, S.; Akhavan, D.; Chakravarti, A.; Cavenee, W.; Mischel, P. Fyn and Src are effectors of oncogenic EGFR signaling in GBM patients. Cancer Res (in press).
  • Yadav, A.; Renfrow, J.; Scholtens, D.; Xie, H.; Duran, G.; Bredel, C.; Vogel, H.; Chandler, J.; Chakravarti, A.; Robe, P.; Das, S.; Scheck, A.; Kessler, J.; Soares, M.B.; Harsh, G.; Bredel, M. Monosomy of Chromosome 10 associated with dysregulation of EGFR signaling in GBMs. JAMA 302(3):325-326, 2009.
  • Palanichamy, K.; Chakravarti, A. Combining drugs and radiotherapy: from the bench to the bedside. Curr Opin Neurol 2009 Sept. 16 (epub ahead of print).
  • Zhang, M.; Siedow, M.; Saia, G.; Chakravarti, A. Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate 2010 Jan. 6.
  •  Colman, H.; Zhang, L.; Sulman, E.P.; McDonald, J.M.; Shooshtari, N.L.; Rivera, A.; Popoff, S.; Nutt, C.L.; Louis, D.N.; Cairncross, J.G.; Gilbert, M.R.; Phillips, H.S.; Mehta, M.P.; Chakravarti, A.; Pelloski, C.E.; Bhat, K.; Feuerstein, B.G.; Jenkins, R.B.; Aldape, K. A multigene predictor of outcome in glioblastoma. Neuro-oncology 12(1):49-57, 2010.
  • Quick, A.; Patel, D.; Hadziahmetovic, M.; Chakravarti, A.; Mehta, M. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5(1):14-27, 2010.
  • Kahn, J.; Batchelor, T.; Chiocca, N.; Loeffler, J.; Chakravarti, A. Long-term outcomes of spinal cord glioma patients treated by radiotherapy. Int J Radiat Oncol Biol Phys. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):232-8.  
  • Zhang, M; Suzuki Y, Siedow, MR; Niemierko, A; Khor, LY; Pollack, A; Zhang, Y; Zietman, AL; Shipley, WU; Chakravarti, A. Survivin Is A Potential Mediator of Prostate Cancer Metastasis; International Journal of Radiation Oncology Biology Phys., 2010 March 13.
  • Zhang, M; Coen, JJ; Suzuki, Y; Siedow, MR; Niemierko, A; Khor, L; Pollack, A; Zang, Y; Zietman, AL; Shipley, WU; Chakravarti, A. Survivin is a potential mediator of prostate cancer metastasis; International Journal of Radiation Oncology Biology Phys., Vol. 78, No. 4, pp. 1095-1103, 2010 November.
  • Mehta, MP; Siker, ML; Wang, M; Porter, K; Nelson, DF; Curran, WJ; Michalski, JM; Souhami, L; Chakravarti, A; Yung, WKA; DelRowe, J; Coughlin, CT. Age as an independent prognostic factor in patients with glioblastoma; a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison; Journal of Neuro-Oncology, 2010 December 13.
  • Bredel, M; Scholtens, DM; Yadav, AK; Alvarez, AA; Renfrow, JJ; Chandler, JP; Yu, IL; Carro, MS; Dai, F; Tagge, MJ, Ferrarese, R; Bredel, C; Phillips, HS; Lukac, PJ; Robe, PA; Weyerbrock, A; Vogel, H; Dubner, S; Mobley, B; He, X; Scheck, AC; Sikic, BI; Aldape, KD; Chakravarti, A; Harsh GR 4th. NFKBIA Deletion in Glioblastomas. N Engl J Med. 2011 Feb 17;364(7):627-37. Epub 2010 Dec, 22.
  • Renfrow, JJ; Scheck, AC; Dhawan, NS; Lukac, PJ; Vogel, H; Chandler, JP; Raizer, JJ; Harsh, GR;  Chakravarti, A; Bredel, M. Gene-protein Correlation in Single Cells. Neuro Oncol  2011 Aug;13(8):880-5
  • Siker, ML, Wang, M; Porter, K; Nelson, DF; Curran, WJ; Michalski, JM, Souhami, L; Chakravarti, A; Yung, WK; Delrowe, J; coughlin, CT: Mehta, MP. Age As An Independent Prognostic Factor in Patients with Glioblastoma: A Radiation Therapy for Oncology Group and American College of Surgeons National Cancer Data Base Comparison. J Neurooncol 2011 Aug; 104(1): 351-6 Epub 2011 Jan 9.
  • Guo, D; Reinitz F; Youssef, M; Hong, C; Nathanson, D; Akavan, D; Kuga, D; Amzajerdi, AN, Soto, H; Zhu S, Babic I; Tanak, K; Dang, J; Iwanami, A; Gini, B; Dejesus, J; Lisiero, DD; Huang, TT; Prins,RM; Wen, PY; Robins, HI; Prados, MD; Deangelis, LM; Mellinghoff, IK; Mehta, MP; James, CD; Chakravarti A; Cloughsey, TF; Tontonoz, P; Mischel, PS. An LXR Agonist Promotes GBM Cell Death Through Inhibition of AN EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. Cancer Discov. 2011 Sept 15;(5):445-456.
  • Chiocca, EA; Aguilar, LK; Bell, SD, Kaur, B; Hardcastle, J; Cavaliere, R; McGregor, J; Lo, S; Ray-Chaudhuri, A; Chakravarti, A; Grecula, J; Newton, H, Harris, KS; Grossman, Task, TW; Baskin, DS; Monterroso, C; Manzanera, AG; Aguilar-Cordova, E; New, PZ. Phase IBStudy of Gene-Mediated Cytotoxic Immunotherapy Adjuvant To Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma. J Clin Oncol. 2011 Sep 20; 29(27):3611-9 Epub 2011 Aug. 15.
  • Hazdiahmetovic, M; Shirai, K; Chakravarti, A. Recent Advancements in Multimodality Treatment of Gliomas. Future Oncol. 2011 Oct; 7(10):1169-83.
  • Shirai, K; Chakravarti, A. Towards Personalized Therapy for Patients with Glioblastoma. Expert Rev Anticancer Ther. 2011 Dec; 11(12):1935-44.
  • Shirai, K; Siedow, MR; Chakravarti A. Antiangiogenic Therapy For Patients with Recurrent and Newly diagnosed Malignant Gliomas. J Oncol. 2012; 2012: 193436. Epub 2011 July 14.
  • Meng, W.; Chakravarti, A.; Lautenschlaeger, T. Combined RASSF1A and RASSF2A promoter methylation analysis as diagnostic biomarker for bladder cancer. Molecular Biology International 2012; 2012:701814.
  • Jacob, N. and Chakravarti, A. Survivin Splice Variants are not essential for Mitotic Progression or Inhibition of Apoptosis Induced by Doxorubicin and Radiation. OncoTargets and Therapy 2012;5:7-20.
  • Waters, J; Sanchez, C.; Sahin, A.; Futalan, D.; Scheer, J.; Akers, J.; Palanichamy, K.; Waterman, P.; Chakravarti, A.; Weissleder, R.; Morse, B.; Marsh, N.; Furfine, E.; Chen, C; Carvajal, I; Carter, B. CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J. Neurooncol 2012 Oct; 110(1):37-48.
  • Kroonen, J.; Artesi, M.; Capraro, V.; Nguyen-Khac, M.T.; Willems, M.; Chakravarti, A.; Bours, V.; Robe, P. Casein kinase 2 inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells. Int J Oncol. 2012 Aug 41(2):776-782.
  • Perry, J.; Okamoto, M.; Guiou, M.; Shirai, K.; Errett, A.; Chakravarti, A. Novel therapies in glioblastoma. Neurol Res int. 2012; 2012:428565.
  • Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M. RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients. Int J Radiat Oncol Biol Phys. 2012 Nov 22. 2013 Apr 1;85(5):1206-11.
  •  Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH, Chakravarti A. Identification of sensitive serum microRNA biomarkers for radiation biodosimetry. PLoS One. 2013;8(2):e57603.
  • Shirai K, Mizui T, Suzuki Y, Okamoto M, Hanamura K, Yoshida Y, Hino M, Noda SE, Al-jahdari WS, Chakravarti A, Shirao T, Nakano T. X irradiation changes dendritic spine morphology and density through reduction of cytoskeletal proteins in mature neurons. Radiat Res. 2013 Jun;179(6):630-6.
  • Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A. Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist. 2013 Jun;18(6):685-6.
  •  Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger T. Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues. PLoS One. 2013 May 16;8(5):e64393
  • Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer. Curr Pharm Des. 2013 Jun 25.
  • Chettiar SN, Cooley JV, Park IH, Bhasin D, Chakravarti A, Li PK, Li C, Jacob NK. Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5429-33.
  • Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncol. 2013 Oct 7.
  • Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, Huebner A, Meng W, White J, Chakravarti A. In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines. Radiat Oncol. 2013 Oct 23;8(1):246.
  • Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2013 May 1;2(3):289-299.
  • Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B,Volinia S, Nakanishi H, Kim T, Suh SS, Ayers LW, Ross P, Croce CM, Chakravarti A, Jin VX, Lautenschlaeger T. MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma. Clin Cancer Res. 2013 Oct 1;19(19):5423-33.
  • Gilbert MR1, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699-708.
  • Ru, P.; Williams, T.; Chakravarti, A.; Guo, D.; Tumor metabolism of malignant gliomas. Cancer 2013, 5(4), 1469-1484.
  • Juratli, T.; Engellandt, K.; Lautenschaleger, T.; Geiger, K.; von Kummer, R.; Cerhova, J.; Chakravarti, A.; Schackert, G. Is there pseudeoprogression in secondary glioblastomas? Int J Radiat Oncol Biol Phys 2013 Dec 1 87(5): 1094-1099.
  • Singh, M.; Leasure, J.; Chronowski, C.; Geier, B.; Bondra, K.; Duan, W.; Hensley, L.; Villalona-Calerno, M.; Li, N.; Vergis, A.; Kurmasheva, R.; Shen, C.; Woods, G.; Sebastian, N.; Fabian, D.; Kaplon, R.; Hammond, S.; Palanichamy, K.; Chakravarti, A.; Houghton, P. FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring PAX3/FOXO1 fusion gene. Clin Cancer Res. 2014 Jul 15;20(14):3884-95. doi: 10.1158/1078-0432.CCR-13-0556. Epub 2014 Apr 30.
  • Yan, F., Alinari, L., Lustberg, M.E., Martin, L.K., Cordero-Nieves, H.M., Banasavadi-Siddegowda, Y., Virk, S., Barnholtz-Sloan, J., Hlavin Bell, E., Wojton, J., Jacob, N.K., Chakravarti, A., Nowicki. M.O., Wu, X., Lapalombella, R., Datta, J., Yu, B., Gordon, K., Haseley, A., Patton, J.P., Smith, P.L.,  Ryu, J., Zhang, X., Mo, X., Marcucci, G., Nuovo, G., Kwon, C.H., Byrd, J.C., Chiocca, E.A., Li, C., Sif, S., Jacob, S., Lawler, S., Kaur, B., and Baiocchi, R.A. (2014) Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Can Res 74(6):1752-65.
  • Ferrarese R, Harsh GR 4th, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel M. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest. 2014 Jul 1;124(7):2861-76. doi: 10.1172/JCI68836. Epub 2014 May 27.
  • Rong Y, Walston S, Welliver MX, Chakravarti A, Quick AM. Improving intra-fractional target position accuracy using a 3D surface surrogate for left breast irradiation using the respiratory-gated deep-inspiration breath-hold technique. PLoS One. 2014 May 22;9(5):e97933. doi: 10.1371/journal.pone.0097933. eCollection 2014.
  • Artesi M, Kroonen J, Bredel M, Nguyen-Khac M, Deprez M, Schoysman L, Poulet C, Chakravarti A, Kim H, Scholtens D, Seute T, Rogister B, Bours V, Robe PA. Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy. Neuro Oncol. 2014 Aug 25. pii: nou215. [Epub ahead of print].
  • Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. 2014 Jul 17. [Epub ahead of print].
  • Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski MC, Kaur B. Changes in BAI1 and Nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther. 2014 Nov 5. pii: molcanther.0659.2014. [Epub ahead of print]
  • Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):497-504. doi: 10.1016/j.ijrobp.2014.11.012. Epub 2015 Jan 30.
  • Walston S, Hamstra DA, Oh K, Woods G, Guiou M, Olshefski RS, Chakravarti A, Williams TM. A multi-institutional experience in pediatric high-grade glioma. Front Oncol. 2015 Feb 18;5:28. doi: 10.3389/fonc.2015.00028. eCollection 2015.
  • Majithia L, Rong Y, Siddiqui F, Hattie T, Gupta N, Weldon M, Chakravarti A, Wong HK, Porcu P, Xu-Welliver M. Treating cutaneous T-cell lymphoma with highly irregular surfaces with photon irradiation using rice as tissue compensator. Front Oncol. 2015 Feb 24;5:49. doi: 10.3389/fonc.2015.00049. eCollection 2015
  • Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL, Martin D, White J, Werner M, Grosu AL, Chakravarti A. A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy. PLoS One. 2015 Mar 11;10(3):e0118745. doi: 10.1371/journal.pone.0118745. eCollection 2015.
  • Woods GM, Bondra K, Chronowski C, Leasure J, Singh M, Hensley L, Cripe TP, Chakravarti A, Houghton PJ. Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. Pediatr Blood Cancer. 2015 Mar 19. doi: 10.1002/pbc.25516. [Epub ahead of print]PMID:25790258.
  • S.A. Walston,1 D. Blakaj,1 B. Kumar,2 M. Choudhary,3 K. Palanichamy,3 N. Nolan,1 E. Miller,1 W.F. Mourad,4 P. Kumar,2 A. Bhatt,1 V. Diavolitsis,1J.C. Grecula,3 M. Old,3 T. Teknos,3 and A. Chakravarti5; Papillomavirus E2 Protein as a Biomarker for Radiation Sensitivityin HPV Associated Head and Neck Squamous Cell Carcinoma.
  • Jan C. Buckner, M.D., Edward G. Shaw, M.D., Stephanie L. Pugh, Ph.D.,Arnab Chakravarti, M.D., Mark R. Gilbert, M.D., Geoffrey R. Barger, M.D.,Stephen Coons, M.D., Peter Ricci, M.D., Dennis Bullard, M.D.,Paul D. Brown, M.D., Keith Stelzer, M.D., David Brachman, M.D.,John H. Suh, M.D., Christopher J. Schultz, M.D., Jean-Paul Bahary, M.D.,Barbara Jean Fisher, M.D., Harold Kim, M.D., Albert D. Murtha, M.D.,Erica Hlavin Bell, Ph.D., Minhee Won, M.A., Minesh P. Mehta, M.D., and Walter J. Curran, Jr., M.D. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. New Eng J Med (Accepted).

  • Cheng, C.; Geng, F.; Liu, J.; Yoo, J.; Wu, X.; Cheng, X.; Euthine, V.; Hu, P.; Guo, J.; Lefai, E.; Kaur, B.; Nohturftt, A.; Ma, J.; Chakravarti, A.; Guo, D. Glucose-mediated N-acetylglycosylation of SCAP is essential for SREBP-1 activation and tumor growth. Cancer Cell (accepted).

  • Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, Bekaii-Saab T, Chakravarti A, Williams TM. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Sci Rep. 2015 Jun 12;5:10867. doi: 10.1038/srep10867.
  • Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, Lee TJ, Luo Z, Liu L, Xu D, Tili E, Jin V, Middleton J, Chakravarti A, Lautenschlaeger T, Croce CM. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4288-97. doi: 10.1073/pnas.1502068112. Epub 2015 Jul 17.
  • Cui R, Kim T, Fassan M, Meng W, Sun HL, Jeon YJ, Vicentini C, Tili E, Peng Y, Scarpa A, Liang G, Zhang YK, Chakravarti A, Croce CM. MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7. Oncotarget. 2015 Sep 8;6(26):21802-15.
  • Estrada-Bernal A, Chatterjee M, Haque SJ, Yang L, Morgan MA, Kotian S, Morrell D, Chakravarti A, Williams TM. MEK Inhibitor GSK1120212-Mediated Radiosensitization of Pancreatic Cancer Cells Involves Inhibition of DNA Double-Strand Break Repair Pathways. Cell Cycle. 2015 Oct 27:0. [Epub ahead of print]
  • Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2015 Oct 27. [Epub ahead of print]
  • Nguyen P, Wuthrick E, Chablani P, Robinson A, Simmons L, Wu C, Arnold M, Harzman AE, Husain S, Schmidt C, Abdel-Misih S, Bekaii-Saab T, Chakravarti A, Williams TM. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J ClinOncol. 2015 Nov 3. [Epub ahead of print].
  • Dr. Kamalakannan Palanichamy, Dr. Shin-ei Noda , Mr. Kevin T. Litzenberg , Mr. John R. Jacob , Mr. Nicolaus Gorden , Disha Patel , Mr. Michael Erkkinen , Mr. Michael Siedow , Dr. Andrea Salavaggione , Dr. Hiroaki Wakimoto , Dr. Deva S. Jeyaretna , Dr. Reddy Gali , Abhik Ray-Chaudhury , Dr. Arnab Chakravarti. Isolation and Characterization of Treatment Resistant Tumor Initiating Cells that are maintained by Cytokine and Growth Factors Secreted by Differentiated Cells. CAN-15-2992 (Cancer Research) – Under Review.
  • Kamalakannan Palanichamy, Krishnan Thirumoorthy, Suman Kanji, Nicolaus Gordon, Rajbir Singh, John R Jacob, Nikhil Sebastian, Kevin T Litzenberg, Disha Patel, Emily Bassett, Brinda Ramasubramanian,Tim Lautenschlaeger, Steven M Fischer, Abhik Ray-Chaudhury and Arnab Chakravarti. Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation. CCR-15-2308 (Clinical Cancer Research) – Under Review
  • Erica Hlavin Bell, PhD1, Stephanie L. Pugh, PhD2, Joseph P. McElroy, PhD1, Mark R. Gilbert, MD3, Minesh Mehta, MD4, Alexander C. Klimowicz, PhD5, Anthony Magliocco, MD6, Markus Bredel, MD, PhD7, Pierre Robe, MD, PhD8, Anca Grosu, MD9, Roger Stupp, MD10, Walter Curran, Jr., MD11, Andrea L Salavaggione, MD1, Jill S. Barnholtz-Sloan, PhD12, Kenneth Aldape, MD13, Deborah T. Blumenthal, MD14, Paul Brown, MD13, Jon Glass, MD15, Luis Souhami, MD, FASTRO16, R. Jeffrey Lee, MD17, David Brachman, MD18, John Flickinger, MD19, Minhee Won, MA2, and Arnab Chakravarti, MD1 RTOG 0525 Development of a Refined Molecular-Based Recursive Partitioning Analysis (RPA) Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based Upon NRG Oncology/RTOG 0525. (In preparation).
  • Hlavin Bell, E., Chakraborty, A., Mo., X., Liu, Z., Shilo, K., Kirste, S., Stegmaier, P., McNulty, M., Karachaliou, N., Rosell, R., Bepler, G., Carbone, D., Chakravarti, A. SMARCA4/BRG1 is a novel predictive biomarker of cisplatin-based chemotherapy in non-small cell lung cancer: A study based on the JBR.10 clinical trial. Clin Can Res. (Under Review).
  • Bell, E.H., Zhang, P., Pugh, S.L., Buckner, J.C., Shaw, E.G., Gilbert, M.R., Barger, G.R., Coons, S., Ricci, P., Bullard, D., Brown, P.D., Stelzer, K., Brachman, D., Suh., J.H., Schultz, C.J., Bahary, J.P., Fisher, B.J., Kim., H., Murtha, A.D., , Won, M., Mehta., M.P., Curran. W.J, and Chakravarti, A. IDH mutations and 1p/19q co-deletions in NRG Oncology/RTOG 9802: Phase III Study of radiation therapy (RT) alone vs RT plus procarbazine, CCNU, and vincristine (PCF) in patients with low grade glioma (LGG). (In preparation).
  • Bell, E.H., Zhang, P., Pugh, S.L., Buckner, J.C., Shaw, E.G., Gilbert, M.R., Barger, G.R., Coons, S., Ricci, P., Bullard, D., Brown, P.D., Stelzer, K., Brachman, D., Suh., J.H., Schultz, C.J., Bahary, J.P., Fisher, B.J., Kim., H., Murtha, A.D., , Won, M., Mehta., M.P., Curran. W.J, and Chakravarti, A. Methylation biomarkers in NRG Oncology/RTOG 9802: Phase III Study of radiation therapy (RT) alone vs RT plus procarbazine, CCNU, and vincristine (PCF) in patients with low grade glioma (LGG). (In preparation).
  • Bell, E.H., Zhang, P., Pugh, S.L., Buckner, J.C., Shaw, E.G., Gilbert, M.R., Barger, G.R., Coons, S., Ricci, P., Bullard, D., Brown, P.D., Stelzer, K., Brachman, D., Suh., J.H., Schultz, C.J., Bahary, J.P., Fisher, B.J., Kim., H., Murtha, A.D., , Won, M., Mehta., M.P., Curran. W.J, and Chakravarti, A. Copy number biomarkers in NRG Oncology/RTOG 9802: Phase III Study of radiation therapy (RT) alone vs RT plus procarbazine, CCNU, and vincristine (PCF) in patients with low grade glioma (LGG). (In preparation).
  • Chang, S., Zhang, P., Cairncross, J.G., Gilbert, M.R., Bahary, J.P., Dolinskas, C., Aldape, K.D., Bell, E.H., Sciff, D., Jaeckle, K., Brown, P.D., Barger, G.R., Werner-Wasik, M., Shih, H., Brachman, D., Penas Prado, M., Robins, Hi., Belanger, K., Schultz, C.J., Chakravarti, A., and Mehta, M. Results of NRG Oncology/RTOG 9813-a phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (In preparation).
  • Bell, E.H., Zhang, P., Cairncross, J.G., Gilbert, M.R., Bahary, J.P., Dolinskas, C., Aldape, K.D., , Sciff, D., Jaeckle, K., Brown, P.D., Barger, G.R., Werner-Wasik, M., Shih, H., Brachman, D., Penas Prado, M., Robins, Hi., Belanger, K., Schultz, C.J., Mehta, M., Chang, S., and Chakravarti, A. IDH mutations and 1p/19q co-deletions in NRG Oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (In preparation).
  • Bell, E.H., Zhang, P., Cairncross, J.G., Gilbert, M.R., Bahary, J.P., Dolinskas, C., Aldape, K.D., , Sciff, D., Jaeckle, K., Brown, P.D., Barger, G.R., Werner-Wasik, M., Shih, H., Brachman, D., Penas Prado, M., Robins, Hi., Belanger, K., Schultz, C.J., Mehta, M., Chang, S., and Chakravarti, A. Methylation Biomarkers in NRG Oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (In preparation).
  • Bell, E.H., Zhang, P., Cairncross, J.G., Gilbert, M.R., Bahary, J.P., Dolinskas, C., Aldape, K.D., , Sciff, D., Jaeckle, K., Brown, P.D., Barger, G.R., Werner-Wasik, M., Shih, H., Brachman, D., Penas Prado, M., Robins, Hi., Belanger, K., Schultz, C.J., Mehta, M., Chang, S., and Chakravarti, A. Copy number biomarkers in NRG Oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (In preparation).
  • Bell, E.H., Zhang, P., Hu, C., Macdonald, D.R., Lesser, G.J., Coons, S.W., Brachman, D.G., Ryu, S., Werner-Wasik, M., Bahary, J.P., Liu, J., Mehta, M., Fisher, B.J., and Chakravarti, A. Methylation Biomarkers in NRG Oncology/RTOG 0424: A Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas. (In preparation).
  • Bell, E.H., Kirste, S., Chakraborty, A., Fleming, J., Drendel, V., McElroy, J., Fabian, D., Manring, I., Jilg, C.A., Schultze-Seemann, W., Zynger, D.L., Martin D., Werner, M., Grosu, A., and Chakravarti, A. A novel methylation-based predictive model for biochemical failure following prostatectomy and post-prostatectomy salvage radiation therapy. (In Preparation).
  • Bell, E.H., Kirste, S., Chakraborty, A., Fleming, J., Drendel, V., McElroy, J., Fabian, D., Manring, I., Jilg, C.A., Schultze-Seemann, W., Zynger, D.L., Martin D., Werner, M., Grosu, A., and Chakravarti, A. A novel copy number-based predictive model for biochemical failure following prostatectomy and post-prostatectomy salvage radiation therapy. (In Preparation).
  • Bell, E.H., Kirste, S., Bassett, E., Drendel, V., McElroy, J., Fabian, D., Manring, I., Jilg, C.A., Schultze-Seemann, W., Zynger, D.L., Martin D., Werner, M., Grosu, A., and Chakravarti, A. A novel proteomic-based predictive model for biochemical failure following prostatectomy and post-prostatectomy salvage radiation therapy. (In Preparation).
  • Bell, E.H., Geurts, M., McElroy, J., Fleming, J., Robe, P., and Chakravarti, A. A novel miRNA-based predictive model for overall survival following radiation and temozolomide in glioblastoma. (In Preparation).
  • Fleming, J., Bell, E.H., Kirste, S., Andrews, K., Drendel, V., McElroy, J., Fabian, D., Manring, I., Jilg, C.A., Schultze-Seemann, W., Zynger, D.L., Martin D., Werner, M., Grosu, A., and Chakravarti, A. The microRNA miR-601 inhibits prostate cancer cell tumorigenesis. (In Preparation).
  • Huebner A, Oehlke O, Lautenschlaeger T, Juratli T, Meng W, Ibrahim A, Li B, Erny D, Robe P, Krex D, Schackert G,Prinz M, Grosu A, and Chakravarti A.
    A Six-Gene Classifier Identifies High Risk Patients within the Heterogeneous Population of Grade II and Grade III Gliomas (In Preparation).
  • Kamalakannan, P., Singh, R., Okamota, M., Jacob, J., Chakravarti, A. Mir-194-3p Suppresses the Tumorigenic Potential of Glioblastoma Stem Cells by Targeting the Canonical NF-κB Pathway (In Preparation).
  • Singh, R., Ramasubramanian, B., Kanji, S., Chakraborty, A., Haque, S.J, and Chakravarti, A. Circulating miRNAs in cancer: Are they worth the hype (In Preparation).

VIEW FULL CV